{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:05:44Z","timestamp":1777727144581,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"AstraZeneca Bulgaria"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors are currently the new standard active agents in chronic lymphocytic leukaemia. This observational study describes the real-world use of frontline treatment in Bulgarian patients with active chronic lymphocytic leukaemia and characterises the patient population receiving these treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DESCRIBE was a physician-chart review study conducted at eight haematology centres across Bulgaria. Adult patients with confirmed active chronic lymphocytic leukaemia requiring frontline treatment initiation after January 2022 were considered for enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 90 patients were included in the study. The mean age (standard deviation) was 62.8 (11.2) years, and 58% were male. The median (range) duration of disease was 6 (0\u2013198) months at the time of frontline treatment initiation and 19.2 (1.2\u2013206.4) months at enrolment. Comorbidities were reported in 58 (64%) patients, with cardiovascular diseases being the most common (57%). Cytogenetic testing rates were lower, particularly for del(11q), tumour protein p53 gene and immunoglobulin heavy chain variable region gene mutation status, which were assessed in only 44%, 21% and 37% of patients, respectively. At the time of frontline treatment initiation, most patients presented with Rai stage II (44%) or Binet stage B (63%). Targeted therapy was used in 77% of cases (46% Bruton tyrosine kinase inhibitors and 31% B-cell lymphoma 2 inhibitors), while chemoimmunotherapy was used in the remaining 23%. Patients with high-risk chronic lymphocytic leukaemia were more likely to receive second-generation Bruton tyrosine kinase inhibitors (odds ratio\u2009=\u20095.59,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and each additional high-risk trait further increased the odds of its use (odds ratio\u2009=\u20092.35,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate a shift towards the adoption of novel therapies in Bulgaria, with Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors now dominating the contemporary frontline treatment landscape (2022\u20132023). Improving the rate of testing for specific high-risk molecular and genetic markers is vital to enhancing outcomes in patients with chronic lymphocytic leukaemia. In the era of proven efficacy of targeted agents, chemoimmunotherapy should be discouraged, in line with international guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03000605261421729","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:27:55Z","timestamp":1771288075000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7059-1411","authenticated-orcid":false,"given":"Vasko","family":"Graklanov","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, University Hospital \u201cSveti Georgi\u201d Plovdiv, Bulgaria and Medical University of Plovdiv, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atanas","family":"Radinoff","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, University Hospital \u201cSveti Ivan Rilski\u201d Sofia, Bulgaria and Medical University Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilina","family":"Micheva","sequence":"additional","affiliation":[{"name":"Clinics of Haematology, \u201cSveta Marina\u201d University Hospital, Varna, Bulgaria and Second Department of Internal Disease, Faculty of Medicine, Medical University Varna, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merlin Erol","family":"Efraim","sequence":"additional","affiliation":[{"name":"Clinics of Haematology, \u201cSveta Marina\u201d University Hospital, Varna, Bulgaria and Second Department of Internal Disease, Faculty of Medicine, Medical University Varna, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Donchev","sequence":"additional","affiliation":[{"name":"Clinical Haematology, Specialized Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria and Medical University Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Yankova","sequence":"additional","affiliation":[{"name":"Clinical Haematology, Specialized Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria and Medical University Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanya","family":"Slavcheva-Popova","sequence":"additional","affiliation":[{"name":"Hematology Clinic - UMBAL, Medical University of Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Naneva","sequence":"additional","affiliation":[{"name":"Hematology Clinic - UMBAL, Medical University of Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgueniy","family":"Hadjiev","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical University Sofia, Sofia, Bulgaria and University Hospital Alexandrovska, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Gercheva-Kyuchukova","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria and Faculty of Medicine, Sofia University St. Kliment Ohridski, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Petrova-Latkova","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria and Faculty of Medicine, Sofia University St. Kliment Ohridski, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Nikolov","sequence":"additional","affiliation":[{"name":"Department of Haematology, Military Medical Academy, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nenov","sequence":"additional","affiliation":[{"name":"AstraZeneca, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Ostoji\u0107","sequence":"additional","affiliation":[{"name":"AstraZeneca, Balkans Cluster, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislava","family":"Krasteva","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanet","family":"Grudeva-Popova","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, University Hospital \u201cSveti Georgi\u201d Plovdiv, Bulgaria and Medical University of Plovdiv, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-021-00973-6"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3145"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26677"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238735"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000534730"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051583"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_8_13_2","unstructured":"European Union. European Union Countries: Bulgaria Overview https:\/\/european-union.europa.eu (2024 accessed 24 November 2024)."},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.15547\/tjs.2015.s.02.021"},{"key":"e_1_3_8_16_2","unstructured":"National Health Insurance Fund Bulgaria. Reimbursement list of drugs in oncology and hematology https:\/\/www.nhif.bg\/bg\/medicine_food\/hospital-drugs\/anti-fatigue (2024 accessed 11 October 2024)."},{"key":"e_1_3_8_17_2","unstructured":"NCPR Bulgaria. National Council on Prices and reimbursement of Medicial Products Bulgaria https:\/\/www.ncpr.bg\/ (2024 accessed 11 October 2024)."},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01054-w"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086066"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14785"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174776"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16859"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18020701"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12343-1"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061228"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000407"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15030047"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000771"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.11.010"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00070"},{"key":"e_1_3_8_32_2","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Patients W.A.I.T. Indicator 2019 Survey https:\/\/www.efpia.eu\/ (2020 accessed 25 October 2024)."},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082076"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.009"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad324"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.322"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.888"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164047"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1517972"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.07.005"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.10.011"},{"key":"e_1_3_8_42_2","first-page":"102","article-title":"Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe","volume":"11","author":"Aurer I","year":"2025","unstructured":"Aurer I, Bulj N, Demirevska L, et\u00a0al. Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. Cardiooncology 2025; 11: 102.","journal-title":"Cardiooncology"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261421729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261421729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261421729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:43Z","timestamp":1777459723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261421729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/03000605261421729"],"URL":"https:\/\/doi.org\/10.1177\/03000605261421729","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"03000605261421729"}}